![“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg?w=350&fit=crop&auto=format)
“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.
|Slideshows|February 20, 2015
Coffee and Cancer Risk
Author(s)Cancer Network Editors
This slide show highlights recent studies that examined coffee consumption as it relates to cancer risk, including melanoma, breast and liver cancers, and more.
Advertisement
References:
1. Holick CN, Smith SG, Giovannucci E, Michaud DS.
2. Galeone C, Tavani A, Pelucchi C, et al.
3. Setiawan VW, Wilkens LR, Hernandez BY, et al. Coffee intake reduces hepatocellular carcinoma risk: The Multiethnic Cohort. American Association for Cancer Research Annual Meeting 2014; April 5–9, 2014; San Diego. Abstr LB-281.
4. Geybels MS, Neuhouser ML, Wright JL, et al.
5. Sinha R, Cross AJ, Daniel CR, et al.
6. Jiang W, Wu Y, Jiang X.
7. Loftfield E, Freedman ND, Graubard BI, et al.
8. Merritt MA, Tzoulaki I, Tworoger SS, et al.
Advertisement
Related to this article
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
5